Login to Your Account

Clinic Roundup

Thursday, July 21, 2011
Talon Therapeutics Inc., of San Mateo, Calif., enrolled its first patient in a Phase I trial of Marqibo (vincristine sulfate liposomes injection) for pediatric use in acute lymphoblastic leukemia. The company said that the drug has potential for solid tumors and hematologic malignancies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription